Orexo to present at the BioCentury Future Leaders in the Biotech Industry Conference

Orexo to present at the BioCentury Future Leaders in the Biotech Industry Conference

Uppsala, Sweden – March 21, 2014 – Orexo AB today announces that the company’s CEO Nikolaj Sørensen will present at the BioCentury 21st Annual Future Leaders in the Biotech Industry Conference in New York at 11:30am, eastern, on Friday, March 28, 2014.

The conference is held at Millennium Broadway Hotel in New York City and attracts the corporate and investment community. The conference schedule can be found on www.biocentury.com/conferences/futureleaders/dates.

The slides from Orexo presentation will subsequently be available on www.orexo.com.

For further information, please contact:
Beata Augenblick, Investor Relations Coordinator, Orexo AB
Tel: +46-706 22 59 93, E-mail: ir@orexo.com

About Orexo
Orexo is a specialty pharmaceutical company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology. The company is commercializing its proprietary product, Zubsolv® (buprenorphine and naloxone), in the United States for maintenance treatment of opioid dependence. Zubsolv is a novel sublingual formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual technologies. Orexo has a portfolio of two approved and revenue generating products currently marketed under license in the EU, US and Japan. Orexo’s development expertise is within the area of reformulation technologies, and especially sublingual formulations. Orexo AB, with its headquarters in Sweden, is listed on NASDAQ-OMX. The largest shareholders are Novo A/S and HealthCap.

For information about Orexo, please visit www.orexo.com

Tags: